The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity

Despite the recent clinical success of T cell checkpoint inhibition targeting the CTLA-4 and PD-1 pathways, many patients either fail to achieve objective responses or they develop resistance to therapy. In some cases, poor responses to checkpoint blockade have been linked to suboptimal CD28 costimu...

Descripción completa

Detalles Bibliográficos
Autores principales: Maurer, Mark F., Lewis, Katherine E., Kuijper, Joseph L., Ardourel, Dan, Gudgeon, Chelsea J., Chandrasekaran, Siddarth, Mudri, Sherri L., Kleist, Kayla N., Navas, Chris, Wolfson, Martin F., Rixon, Mark W., Swanson, Ryan, Dillon, Stacey R., Levin, Steven D., Kimbung, Yengo Raymond, Akutsu, Masato, Logan, Derek T., Walse, Björn, Swiderek, Kristine M., Peng, Stanford L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980021/
https://www.ncbi.nlm.nih.gov/pubmed/35379805
http://dx.doi.org/10.1038/s41467-022-29286-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980021/
https://www.ncbi.nlm.nih.gov/pubmed/35379805
http://dx.doi.org/10.1038/s41467-022-29286-5

Ejemplares similares